A Phase 2 interventional study of BR1400-1 and BR1400-2 in Essential Hypertension, sponsored by Boryung Pharmaceutical Co., Ltd. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.
Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd — 8 open to participants now, 8 under way, 1 of them phase 3. Essential Hypertension · Boryung Pharmaceutical Co., Ltd.
Among the 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd, this one is the 2nd largest by planned enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2026, is one of 4 in phase 2, and was the 39th registered.
481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.
Browse Essential Hypertension studies →8 of the 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:
Boryung Pharmaceutical Co., Ltd · Sites in Indonesia, Korea, Republic of
Ages 19+
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+
Boryung Pharmaceutical Co., Ltd
Ages 19+
Boryung Pharmaceutical Co., Ltd
Ages 19+ · Healthy volunteers
Boryung Pharmaceutical Co., Ltd
Ages 19+ · Healthy volunteers
By country, each count listing its studies:
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 330 is above the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 58 across the 39 interventional studies, 4,542 across the 5 observational. Of the 36 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boryung Pharmaceutical Co., Ltd is the lead sponsor of 143 studies on the registry; 23 are open to participants now.
2 of the studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06220773Phase 3Boryung Pharmaceutical Co., LtdA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | 2026-12 |
| NCT07373613Boryung Pharmaceutical Co., LtdA Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
\<Screening Visit (V1)>
Patients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the screening (Visit 1) meets the following criteria:
For patients receiving antihypertensive therapy at the screening (Visit 1), those for whom the investigator determines that it is medically appropriate to temporarily discontinue their current antihypertensive treatment during the study.
\<Baseline Visit (V2)>
Patients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the baseline (Visit 2) prior to randomization meets the following criteria:
Exclusion Criteria:
Patients will receive tablet BR1400-1 + BR1400-B (Placebo of BR1400-2 \& BR1400-4)+ BR1400-C (Placebo of BR1400-5)
Drug: BR1400-1 · Drug: BR1400-B · Drug: BR1400-C
Patients will receive BR1400-A (Placebo of BR1400-1 \& BR1400-3) + BR1400-2 + BR1400-C (Placebo of BR1400-5)
Drug: BR1400-2 · Drug: BR1400-A · Drug: BR1400-C
Patients will receive BR1400-3 + BR1400-B (Placebo of BR1400-2 \& BR1400-4) + BR1400-C (Placebo of BR1400-5)
Drug: BR1400-3 · Drug: BR1400-B · Drug: BR1400-C
Patients will receive BR1400-A (Placebo of BR1400-1 \& BR1400-3) + BR1400-4 + BR1400-C (Placebo of BR1400-5)
Drug: BR1400-4 · Drug: BR1400-A · Drug: BR1400-C
Patients will receive BR1400-A (Placebo of BR1400-1 \& BR1400-3) + BR1400-B (Placebo of BR1400-2 \& BR1400-4) + BR1400-5
Drug: BR1400-5 · Drug: BR1400-A · Drug: BR1400-B
Patients will receive BR1400-A (Placebo of BR1400-1 \& BR1400-3) + BR1400-B (Placebo of BR1400-2 \& BR1400-4) + BR1400-C (Placebo of BR1400-5)
Drug: BR1400-A · Drug: BR1400-B · Drug: BR1400-C
One tablet administered alone
One tablet administered alone
One tablet administered alone
One tablet administered alone
One tablet administered alone
One tablet administered alone
Also known as: Placebo
One tablet administered alone
Also known as: Placebo
One tablet administered alone
Also known as: Placebo
Change from baseline to treatment of 8 weeks in MSSBP
Time frame: 8 weeks
Start is estimated for Mar 2026; primary completion for Feb 2027, 11 months later.
Of 16 phase 2 interventional studies under Essential Hypertension, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boryung Pharmaceutical Co., Ltd →